Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

NeuroMetrix, Inc. is a healthcare company, which engages in the research, development, and trade of medical equipment and consumables. The company is headquartered in Waltham, Massachusetts and currently employs 42 full-time employees. The firm is engaged in the sale of medical equipment, and consumables and accessories. The company has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
Website: neurometrix.com



Growth: Bad revenue growth rate 0.0%, there is acceleration compared to average historical growth rates -2.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -62.5%. On average the margin is decreasing steadily. Gross margin is high, +64.8%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 50% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -56.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 64.2% higher than minimum and 84.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.7x by EV / Sales multiple

Key Financials (Download financials)

Ticker: NURO
Share price, USD:  (0.0%)4.58
year average price 4.23  


year start price 2.92 2024-08-09

min close price 2.79 2024-08-12

max close price 4.60 2025-03-24

current price 4.58 2025-08-08
Common stocks: 8 520 025

Dividend Yield:  0.0%
EV / Sales: 4.8x
Margin (EBITDA LTM / Revenue): -62.5%
Fundamental value created in LTM:
Market Cap ($m): 39
Net Debt ($m): -1
EV (Enterprise Value): 38
Price to Book: 2.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-12-18prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURO

2024-12-17businesswire.com

NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders

2024-12-17globenewswire.com

NeuroMetrix to be Acquired by electroCore

2024-11-06zacks.com

NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth

2024-08-13globenewswire.com

NeuroMetrix Reiterates its Review of Strategic Alternatives

2024-08-10seekingalpha.com

NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript

2024-07-31globenewswire.com

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

2024-02-22Seeking Alpha

NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript

2024-01-08GlobeNewsWire

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

2023-09-28GlobeNewsWire

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NURO NURO NURO NURO NURO NURO NURO NURO NURO
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-05 2024-08-06 2024-05-15 2024-03-01 2023-10-26 2023-07-27 2023-05-03 2023-03-22 2022-10-20
acceptedDate 2024-11-05 16:23:45 2024-08-06 16:24:24 2024-05-15 11:19:27 2024-03-01 17:07:47 2023-10-26 16:20:54 2023-07-27 16:03:32 2023-05-03 16:35:37 2023-03-22 16:57:58 2022-10-20 16:11:15
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 587 314 769 148 1M 1M 1M 2M 2M 2M 2M
costOfRevenue 275 357 277 229 576 539 469 772 421 382 536 486 526 372 617 267 693 571
grossProfit 311 957 491 919 517 017 847 974 781 782 1M 1M 1M 1M
grossProfitRatio 0.531 0.64 0.473 0.644 0.65 0.676 0.695 0.666 0.648
researchAndDevelopmentExpenses 299 739 266 932 943 552 732 372 592 654 753 509 699 425 538 395 1M
generalAndAdministrativeExpenses 1M 2M 2M 1M 1M 1M 1M 918 214 1M
sellingAndMarketingExpenses 441 171 435 014 1M 860 635 943 795 744 963 815 872 629 969 810 209
sellingGeneralAndAdministrativeExpenses 2M 2M 3M 2M 2M 2M 2M 2M 2M
otherExpenses 0 327 718 205 255 198 146 192 161 86 426 135 895 0 0
operatingExpenses 2M 2M 4M 3M 3M 3M 3M 2M 3M
costAndExpenses 2M 3M 4M 3M 3M 3M 3M 3M 4M
interestIncome 8412 13 005 19 162 9406 25 378 0 0 0 0
interestExpense 0 0 0 135 895 0 0 -135 895 -164 597 -106 737
depreciationAndAmortization 59 864 91 897 24 908 43 812 10 513 10 222 10 222 0 12 893
ebitda -2M -2M -3M -2M -2M -2M -2M -856 467 -2M
ebitdaratio -2.864 -2.258 -2.953 -1.391 -1.63 -0.98 -0.991 -0.464 -0.864
operatingIncome -2M -2M -3M -2M -2M -2M -2M -856 467 -2M
operatingIncomeRatio -2.966 -2.378 -2.976 -1.409 -1.63 -0.98 -0.991 -0.464 -0.87
totalOtherIncomeExpensesNet 233 822 340 723 224 416 207 553 192 161 86 426 135 895 164 597 106 737
incomeBeforeTax -2M -1M -3M -2M -2M -2M -2M -691 870 -2M
incomeBeforeTaxRatio -2.568 -1.935 -2.77 -1.252 -1.47 -0.928 -0.913 -0.375 -0.816
incomeTaxExpense 0 3 2 5 -10 513 -10 222 -135 895 -10 221 -106 737
netIncome -2M -1M -3M -2M -2M -2M -1M -681 649 -1M
netIncomeRatio -2.568 -1.935 -2.77 -1.252 -1.47 -0.928 -0.834 -0.369 -0.762
eps -0.75 -0.74 -1.67 -1.08 -1.66 -0.2 -0.18 -0.088 -0.21
epsdiluted -0.75 -0.74 -1.67 -1.08 -1.66 -0.2 -0.18 -0.088 -0.21
weightedAverageShsOut 2M 2M 2M 2M 1M 8M 8M 8M 7M
weightedAverageShsOutDil 2M 2M 2M 2M 1M 8M 8M 8M 7M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NURO NURO NURO NURO NURO NURO NURO NURO NURO
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-05 2024-08-06 2024-05-15 2024-03-01 2023-10-26 2023-07-27 2023-05-03 2023-03-22 2022-10-20
acceptedDate 2024-11-05 16:23:45 2024-08-06 16:24:24 2024-05-15 11:19:27 2024-03-01 17:07:47 2023-10-26 16:20:54 2023-07-27 16:03:32 2023-05-03 16:35:37 2023-03-22 16:57:58 2022-10-20 16:11:15
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 921 520 2M 1M 2M 1M 2M 2M 4M 2M
shortTermInvestments 14M 15M 16M 16M 16M 17M 9M 17M 19M
cashAndShortTermInvestments 15M 16M 18M 18M 18M 20M 20M 21M 21M
netReceivables 149 092 280 566 469 650 518 823 614 381 746 725 576 281 646 771 702 459
inventory 1M 1M 1M 2M 2M 2M 2M 2M 1M
otherCurrentAssets 381 876 315 662 611 735 779 039 3M 3M 3M 3M 845 649
totalCurrentAssets 17M 18M 20M 21M 21M 22M 23M 24M 23M
propertyPlantEquipmentNet 366 930 426 794 485 795 543 599 554 729 457 697 497 479 536 228 573 984
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 26 400 26 399 26 400 26 400 26 400 26 400 26 400 26 400 26 400
totalNonCurrentAssets 393 330 453 193 512 195 569 999 581 129 484 097 523 879 562 628 600 384
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 17M 19M 21M 21M 21M 23M 24M 25M 24M
accountPayables 347 641 314 000 144 553 215 509 225 474 181 462 400 299 368 082 539 379
shortTermDebt 142 621 296 782 148 391 148 391 148 391 148 391 148 391 148 391 148 391
taxPayables 130 308 132 708 143 185 141 672 128 986 128 353 132 045 131 621 143 136
deferredRevenue 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 589 301 846 260 2M 876 739 886 501 880 076 868 265 589 939 1M
totalCurrentLiabilities 1M 2M 2M 1M 1M 1M 1M 1M 2M
longTermDebt 0 28 210 60 946 92 485 122 870 152 143 180 345 207 516 233 693
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 -1 -1 0 0 0 0 -454 077
totalNonCurrentLiabilities 0 28 210 60 945 92 484 122 870 152 143 180 345 207 516 233 693
otherLiabilities 0 0 1 1 0 0 0 0 0
capitalLeaseObligations 0 176 601 60 946 92 485 122 870 152 143 180 345 207 516 382 084
totalLiabilities 1M 2M 2M 1M 1M 1M 2M 1M 2M
preferredStock 1 1 1 1 1 1 1 1 1
commonStock 203 202 199 152 859 858 778 778 714
retainedEarnings -216M -215M -213M -210M -208M -207M -205M -204M -203M
accumulatedOtherComprehensiveIncomeLoss 83 853 112 171 247 177 240 171 206 869 168 721 65 874 0 0
othertotalStockholdersEquity 232M 232M 232M 230M 228M 228M 227M 227M 225M
totalStockholdersEquity 16M 17M 19M 20M 20M 21M 22M 23M 22M
totalEquity 16M 17M 19M 20M 20M 21M 22M 23M 22M
totalLiabilitiesAndStockholdersEquity 17M 19M 21M 21M 21M 23M 24M 25M 24M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 17M 19M 21M 21M 21M 23M 24M 25M 24M
totalInvestments 14M 15M 16M 16M 16M 17M 9M 17M 19M
totalDebt 142 621 176 601 209 337 240 876 122 870 152 143 180 345 355 907 382 084
netDebt -778 899 -1M -1M -1M -1M -2M -2M -4M -1M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NURO NURO NURO NURO NURO NURO NURO NURO NURO
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-05 2024-08-06 2024-05-15 2024-03-01 2023-10-26 2023-07-27 2023-05-03 2023-03-22 2022-10-20
acceptedDate 2024-11-05 16:23:45 2024-08-06 16:24:24 2024-05-15 11:19:27 2024-03-01 17:07:47 2023-10-26 16:20:54 2023-07-27 16:03:32 2023-05-03 16:35:37 2023-03-22 16:57:58 2022-10-20 16:11:15
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -2M -1M -3M -2M -2M -2M -2M -691 870 -2M
depreciationAndAmortization 59 864 91 897 24 908 24 755 10 513 10 222 10 222 10 221 12 893
deferredIncomeTax 0 0 0 -36 868 0 0 0 0 0
stockBasedCompensation 203 870 176 148 216 164 180 131 221 268 132 745 165 361 168 139 161 951
changeInWorkingCapital -322 546 183 138 838 147 192 306 -353 976 -35 078 322 952 -1M -700 327
accountsReceivables 131 474 189 084 49 174 95 557 132 344 -170 444 70 490 55 688 -154 684
inventory 20 283 21 033 13 781 107 181 -82 624 164 130 -196 548 -914 448 -187 861
accountsPayables 33 641 169 447 -70 956 -9965 44 012 -218 837 32 217 -171 297 138 807
otherWorkingCapital -507 944 -196 426 846 148 -467 -447 708 190 073 416 793 -353 215 -496 589
otherNonCashItems -225 410 -347 340 142 935 -161 278 -170 949 -21 929 -45 778 413 788 -96 003
netCashProvidedByOperatingActivities -2M -1M -2M -1M -2M -1M -1M -1M -2M
investmentsInPropertyPlantAndEquipment 3 -3 0 -45 366 -138 176 0 0 -13 432 -9750
acquisitionsNet 0 0 0 -143 365 -2M 0 0 0 0
purchasesOfInvestments -10M -11M -7M -7M -6M -7M -9M -22M -2M
salesMaturitiesOfInvestments 12M 13M 8M 7M 8M 8M 9M 0 0
otherInvestingActivites -3 2M 138 286 143 365 2M 0 0 24M 0
netCashUsedForInvestingActivites 1M 2M 138 286 97 999 2M 237 279 -836 984 2M -2M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 2601 1M 2M 1426 700 120 0 2M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -1M 0 1M 2M 1426 0 0 0 0
netCashUsedProvidedByFinancingActivities 0 2601 1M 2M 1426 700 120 0 2M 0
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash -685 454 347 044 -472 016 271 393 -402 396 -513 670 -2M 2M -4M
cashAtEndOfPeriod 921 520 2M 1M 2M 1M 2M 2M 4M 2M
cashAtBeginningOfPeriod 2M 1M 2M 1M 2M 2M 4M 2M 6M
operatingCashFlow -2M -1M -2M -1M -2M -1M -1M -1M -2M
capitalExpenditure 3 -3 0 -45 366 -138 176 0 0 -13 432 -9750
freeCashFlow -2M -1M -2M -1M -2M -1M -1M -1M -2M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-10-27 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-10-20 ET (fiscal 2022 q3)
2022 q2
2022-07-21 ET (fiscal 2022 q2)
2022 q1
2022-04-26 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-08-13 18:47 ET
NeuroMetrix Reiterates its Review of Strategic Alternatives
2024-08-06 11:00 ET
NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options
2024-07-31 18:03 ET
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call
2024-05-15 20:00 ET
NeuroMetrix Reports Q1 2024 Business Highlights
2024-04-19 12:00 ET
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
2024-03-14 13:00 ET
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
2024-03-13 13:00 ET
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
2024-03-12 12:00 ET
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
2024-03-08 16:00 ET
RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
2024-03-04 13:00 ET
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
2024-02-22 12:00 ET
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
2024-02-15 14:00 ET
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
2024-02-13 14:00 ET
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
2024-01-08 14:43 ET
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
2023-12-12 14:00 ET
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
2023-12-05 14:00 ET
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
2023-11-20 14:00 ET
NeuroMetrix Announces One-for-Eight Reverse Stock Split
2023-10-30 13:00 ET
NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023
2023-10-26 11:00 ET
NeuroMetrix Reports Q3 2023 Business Highlights
2023-10-23 15:13 ET
NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
2023-10-02 13:00 ET
NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia
2023-09-28 16:19 ET
NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023
2023-08-30 13:00 ET
NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023
2023-07-27 11:00 ET
NeuroMetrix Reports Q2 2023 Business Highlights
2023-07-20 17:00 ET
NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
2023-07-11 13:00 ET
NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
2023-06-28 13:00 ET
Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
2023-06-07 13:00 ET
Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study
2023-05-31 13:00 ET
Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
2023-05-03 11:00 ET
NeuroMetrix Reports Q1 2023 Financial Results
2023-04-28 13:21 ET
NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
2023-03-21 13:00 ET
NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
2023-02-23 12:00 ET
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
2023-02-16 19:58 ET
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
2023-01-23 14:00 ET
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
2022-11-08 14:00 ET
NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
2022-11-03 13:00 ET
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
2022-10-20 11:00 ET
NeuroMetrix Reports Q3 2022 Financial Results
2022-10-12 19:47 ET
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
2022-09-01 13:00 ET
NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business
2022-07-21 11:00 ET
NeuroMetrix Reports Q2 2022 Financial Results
2022-07-14 15:32 ET
NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call
2022-06-28 13:00 ET
NeuroMetrix Appoints Brad Fluegel to its Board of Directors
2022-05-19 13:00 ET
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
2022-04-26 11:00 ET
NeuroMetrix Reports Q1 2022 Financial Results
2022-04-19 13:00 ET
NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
2022-02-24 14:00 ET
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
2022-01-27 12:00 ET
NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
2022-01-20 17:10 ET
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
2022-01-18 14:00 ET
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
2022-01-10 14:00 ET
NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships
2022-01-05 14:00 ET
NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022
2021-10-21 11:00 ET
NeuroMetrix Reports Q3 2021 Financial Results
2021-10-20 13:00 ET
NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care
2021-10-14 13:00 ET
NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call
2021-10-06 22:42 ET
NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device
2021-10-05 13:00 ET
NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry Partner
2021-07-26 13:00 ET
NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia
2021-07-22 11:00 ET
NeuroMetrix Reports Q2 2021 Financial Results
2021-07-20 13:00 ET
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology
2021-07-15 13:00 ET
NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call
2021-06-15 13:00 ET
NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial
2021-06-09 12:00 ET
NeuroMetrix Announces That Top-Line Results from a Randomized Controlled Trial of Quell® for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences
2021-04-22 11:00 ET
NeuroMetrix Reports Q1 2021 Financial Results
2021-04-15 17:00 ET
NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call
2021-01-28 12:00 ET
NeuroMetrix Reports Q4 and Full Year 2020 Financial Results
2021-01-22 16:05 ET
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call
2020-10-22 11:00 ET
NeuroMetrix Reports Q3 2020 Financial Results
2020-10-15 15:00 ET
NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call
2020-09-22 11:00 ET
NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device
2020-09-21 17:00 ET
NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology
2020-09-04 11:00 ET
NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference
2020-09-01 17:00 ET
NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity
2020-08-20 18:11 ET
NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial
2020-08-10 14:00 ET
Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free
2020-07-23 11:00 ET
NeuroMetrix Reports Q2 2020 Financial Results
2020-07-16 19:14 ET
NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call
2020-07-09 17:00 ET
NeuroMetrix Reports DPNCheck® Expansion in China
2020-06-25 17:00 ET
NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
2020-06-10 17:00 ET
NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device
2020-04-23 11:00 ET
NeuroMetrix Reports Q1 2020 Financial Results
2020-04-16 17:30 ET
NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia
2020-04-16 15:00 ET
NeuroMetrix, Inc. Announces Date for First Quarter 2020 Financial Results Conference Call
2020-04-10 17:42 ET
NeuroMetrix Announces 2020 Annual Meeting of Shareholders Will Be Held in Virtual Meeting Format Only
2020-03-11 15:00 ET
NeuroMetrix Provides Quell® Technology Commercial Strategy and Pipeline Update
2020-03-05 17:14 ET
NeuroMetrix Reports Clinical Studies Recently Published on DPNCheck®
2020-02-25 18:58 ET
NeuroMetrix Reports Scientific Presentations at the American Academy of Pain Medicine 2020 Annual Meeting
2020-01-27 12:00 ET
NeuroMetrix Reports Q4 and Full Year 2019 Financial Results
2020-01-22 15:43 ET
NeuroMetrix, Inc. 2019 Financial Conference Call Rescheduled to Monday January 27, 2020
2020-01-17 17:49 ET
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2019 Financial Results Conference Call
2019-11-18 16:50 ET
NeuroMetrix Announces One-for-Ten Reverse Split
2019-10-17 11:00 ET
NeuroMetrix Reports Q3 2019 Financial Results
2019-10-15 15:00 ET
NeuroMetrix Announces Updates to Quell 2.0 Commercial Strategy
2019-10-10 15:00 ET
NeuroMetrix, Inc. Announces Date for Third Quarter 2019 Financial Results Conference Call

SEC forms

Show financial reports only

SEC form 10
2025-03-31 14:43 ET
NeuroMetrix reported for 2024 q4
SEC form 10
2025-03-31 00:00 ET
NeuroMetrix reported for 2024 q4
SEC form 10
2024-11-05 16:23 ET
NeuroMetrix reported for 2024 q3
SEC form 8
2024-11-05 07:12 ET
NeuroMetrix reported for 2024 q3
SEC form 8
2024-11-05 07:12 ET
NeuroMetrix published news for 2024 q3
SEC form 8
2024-08-06 00:00 ET
NeuroMetrix published news for 2024 q2
SEC form 8
2024-08-06 00:00 ET
NeuroMetrix reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
NeuroMetrix reported for 2024 q2
SEC form 10
2024-05-15 00:00 ET
NeuroMetrix reported for 2024 q1
SEC form 10
2024-03-01 00:00 ET
NeuroMetrix reported for 2023 q4
SEC form 8
2024-02-22 00:00 ET
NeuroMetrix reported for 2023 q4
SEC form 8
2024-02-22 00:00 ET
NeuroMetrix published news for 2023 q4
SEC form 10
2023-10-26 16:20 ET
NeuroMetrix reported for 2023 q3
SEC form 8
2023-10-26 07:11 ET
NeuroMetrix reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
NeuroMetrix reported for 2023 q3
SEC form 10
2023-07-27 16:03 ET
NeuroMetrix reported for 2023 q2
SEC form 6
2023-07-27 07:24 ET
NeuroMetrix reported for 2023 q2
SEC form 10
2023-07-27 00:00 ET
NeuroMetrix reported for 2023 q2
SEC form 8
2023-07-27 00:00 ET
NeuroMetrix reported for 2023 q2
SEC form 10
2023-05-03 00:00 ET
NeuroMetrix reported for 2023 q1
SEC form 8
2023-05-03 00:00 ET
NeuroMetrix reported for 2023 q1
SEC form 6
2023-03-30 12:58 ET
NeuroMetrix published news for 2022 q4
SEC form 10
2023-03-22 16:57 ET
NeuroMetrix reported for 2022 q4
SEC form 10
2023-03-22 00:00 ET
NeuroMetrix reported for 2022 q4
SEC form 6
2023-03-10 16:05 ET
NeuroMetrix published news for 2022 q4
SEC form 6
2023-02-23 07:18 ET
NeuroMetrix reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
NeuroMetrix reported for 2022 q4
SEC form 10
2022-10-20 16:11 ET
NeuroMetrix reported for 2022 q3
SEC form 6
2022-10-20 07:15 ET
NeuroMetrix published news for 2022 q3
SEC form 10
2022-10-20 00:00 ET
NeuroMetrix reported for 2022 q3
SEC form 10
2022-07-21 16:56 ET
NeuroMetrix reported for 2022 q2
SEC form 6
2022-07-21 07:13 ET
NeuroMetrix published news for 2022 q2
SEC form 10
2022-07-21 00:00 ET
NeuroMetrix reported for 2022 q2
SEC form 6
2022-07-06 15:01 ET
NeuroMetrix published news for 2022 q2
SEC form 6
2022-06-28 15:41 ET
NeuroMetrix published news for 2022 q1
SEC form 6
2022-05-03 14:03 ET
NeuroMetrix published news for 2022 q1
SEC form 10
2022-04-26 12:39 ET
NeuroMetrix reported for 2022 q1
SEC form 6
2022-04-26 07:10 ET
NeuroMetrix published news for 2022 q1
SEC form 10
2022-04-26 00:00 ET
NeuroMetrix reported for 2022 q1
SEC form 8
2022-04-26 00:00 ET
NeuroMetrix reported for 2022 q1
SEC form 6
2022-03-24 08:01 ET
NeuroMetrix published news for 2021 q4
SEC form 10
2022-01-28 00:00 ET
NeuroMetrix published news for 2021 q4
SEC form 10
2022-01-27 21:48 ET
NeuroMetrix published news for 2021 q4
SEC form 6
2022-01-27 07:14 ET
NeuroMetrix published news for 2021 q4
SEC form 8
2022-01-27 00:00 ET
NeuroMetrix published news for 2021 q4
SEC form 6
2021-12-10 16:26 ET
NeuroMetrix published news for 2021 q3
SEC form 6
2021-12-03 16:06 ET
NeuroMetrix published news for 2021 q3
SEC form 6
2021-10-22 16:30 ET
NeuroMetrix published news for 2021 q3
SEC form 10
2021-10-21 15:59 ET
NeuroMetrix published news for 2021 q3
SEC form 6
2021-10-21 07:13 ET
NeuroMetrix published news for 2021 q3
SEC form 10
2021-10-21 00:00 ET
NeuroMetrix published news for 2021 q3
SEC form 6
2021-08-13 07:58 ET
NeuroMetrix published news for 2021 q2
SEC form 10
2021-07-22 10:36 ET
NeuroMetrix published news for 2021 q2
SEC form 6
2021-07-22 07:28 ET
NeuroMetrix published news for 2021 q2
SEC form 10
2021-07-22 00:00 ET
NeuroMetrix published news for 2021 q2
SEC form 6
2021-06-30 16:04 ET
NeuroMetrix published news for 2021 q1
SEC form 6
2021-06-25 13:47 ET
NeuroMetrix published news for 2021 q1
SEC form 6
2021-06-11 16:26 ET
NeuroMetrix published news for 2021 q1
SEC form 6
2021-05-11 11:29 ET
NeuroMetrix published news for 2021 q1
SEC form 6
2021-04-27 10:14 ET
NeuroMetrix published news for 2021 q1
SEC form 10
2021-04-22 16:09 ET
NeuroMetrix published news for 2021 q1
SEC form 6
2021-04-22 07:26 ET
NeuroMetrix published news for 2021 q1
SEC form 10
2021-04-22 00:00 ET
NeuroMetrix published news for 2021 q1
SEC form 6
2021-04-15 07:49 ET
NeuroMetrix published news for 2021 q1
SEC form 6
2021-03-16 13:16 ET
NeuroMetrix published news for 2020 q4
SEC form 6
2021-02-26 16:26 ET
NeuroMetrix published news for 2020 q4
SEC form 10
2021-01-28 20:26 ET
NeuroMetrix published news for 2020 q4
SEC form 6
2021-01-28 07:07 ET
NeuroMetrix published news for 2020 q4
SEC form 6
2020-12-31 14:16 ET
NeuroMetrix published news for 2020 q3
SEC form 10
2020-10-22 11:34 ET
NeuroMetrix published news for 2020 q3
SEC form 6
2020-10-22 07:42 ET
NeuroMetrix published news for 2020 q3